Partner > AffiRiS
AFFiRiS AG develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other serious diseases. The company has established its AFFITOM®E platform technologies. It employs 30 highly qualified members of staff on 600m² of rented laboratory facilities at the Campus Vienna Biocenter (www.affiris.com).
AFFITOP and AFFITOM®E are registered trademarks of AFFiRiS AG.